Prevention of Bone Metastases

1. Front Matter

   Pages i-ix

   PDF

2. Preclinical Models that Illuminate the Bone Metastasis Cascade

   • Geertje van der Horst, Gabri van der Pluijm

   Pages 1-31

3. The Role of Bone Microenvironment, Vitamin D and Calcium

   • Daniele Santini, Francesco Pantano, Bruno Vincenzi, Giuseppe Tonini, Francesco Bertoldo

   Pages 33-64

4. Bisphosphonates: Prevention of Bone Metastases in Breast Cancer

   • Michael Gnant, Peter Dubsky, Peyman Hadji

   Pages 65-91

5. Bisphosphonates: Prevention of Bone Metastases in Lung Cancer

   • Lynn Decoster, Filippo de Marinis, Kostas Syrigos, Vera Hirsh, Kristiaan Nackaerts

   Pages 93-108

6. Bisphosphonates: Prevention of Bone Metastases in Prostate Cancer

   • Fred Saad, Jean-Baptiste Lattouf

   Pages 109-126

7. Targeting Bone in Myeloma

   • G. J. Morgan, Ping Wu

   Pages 127-143

8. Combinations of Bisphosphonates and Classical Anticancer Drugs: A Preclinical Perspective

   • Maria Michailidou, Ingunn Holen

   Pages 145-169

9. Perspectives in the Elderly Patient: Benefits and Limits of Bisphosphonates and Denosumab

   • Daniele Santini, Maria Elisabetta Fratto, Matti Aapro

   Pages 171-185

10. Denosumab: First Data and Ongoing Studies on the Prevention of Bone Metastases

    • Roger von Moos, Tomas Skacel

    Pages 187-196

11. Diagnostic and Prognostic Use of Bone Turnover Markers

    • Markus Joerger, Jens Huober

    Pages 197-223

12. Osteolytic and Osteoblastic Bone Metastases: Two Extremes of the Same Spectrum?

    • Angelica Ortiz, Sue-Hwa Lin

    Pages 225-233

Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with breast, lung, and prostate cancer and disease progression in cases of multiple myeloma. The combined use of bisphosphonates and cytostatics is also discussed, with a report on first clinical data. Further topics addressed include the significance of the bone microenvironment, special issues in the elderly patient, the use of bone turnover markers, and initial findings obtained with denosumab.

• Bisphosphonates
• Bone metastases
• Breast cancer
• Prostate cancer
• Zoledronic acid
• surgical oncology

• , Dept. of Medical Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland

  Markus Joerger

• Chirurgische Klinik, Abt. Allgemeine Chirurgie, Universitätsklinikum Wien, Wien, Austria

  Michael Gnant

Policies and ethics